Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
CD8-Positive T-Lymphocytes
/ drug effects
Cell Line, Tumor
/ transplantation
Chemoradiotherapy
/ methods
Disease Models, Animal
Dose Fractionation, Radiation
Humans
Lymphocytes, Tumor-Infiltrating
/ drug effects
Lymphoma
/ pathology
Mice
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Tumor Microenvironment
/ drug effects
antitumor immunity
fractionated radiotherapy
programmed death ligand-1
programmed death-1
scheme
Journal
Cancer biology & therapy
ISSN: 1555-8576
Titre abrégé: Cancer Biol Ther
Pays: United States
ID NLM: 101137842
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
24
12
2018
medline:
7
7
2020
entrez:
22
12
2018
Statut:
ppublish
Résumé
The programmed death (PD) pathway is frequently present in the tumor microenvironment (TME) and suppresses tumor immunity by inhibiting the activity of tumor-infiltrating lymphocytes (TILs), particularly, CD8
Identifiants
pubmed: 30572778
doi: 10.1080/15384047.2018.1550569
pmc: PMC6605991
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Pdcd1 protein, mouse
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
666-679Références
Immunol Lett. 2011 Dec 30;141(1):74-82
pubmed: 21893096
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):677-679
pubmed: 29280462
Clin Cancer Res. 2013 Jan 15;19(2):462-8
pubmed: 23169436
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Immunol Rev. 2007 Dec;220:47-59
pubmed: 17979839
Front Immunol. 2016 Dec 22;7:610
pubmed: 28066420
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Trends Cancer. 2015 Sep 1;1(1):66-75
pubmed: 26457331
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Radiat Environ Biophys. 2014 Mar;53(1):1-29
pubmed: 24141602
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
Immunol Rev. 2017 Nov;280(1):249-279
pubmed: 29027221
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Clin Cancer Res. 2018 Jan 15;24(2):259-265
pubmed: 28751442
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Cancer Lett. 2015 Jan 1;356(1):82-90
pubmed: 24125863
Oncoimmunology. 2017 May 19;6(7):e1329071
pubmed: 28811971
Oral Oncol. 2015 Mar;51(3):221-8
pubmed: 25500094
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Invest. 2002 Mar;109(5):651-9
pubmed: 11877473
Immunol Rev. 2017 Nov;280(1):231-248
pubmed: 29027224
J Ethnopharmacol. 2009 Sep 7;125(2):310-7
pubmed: 19559777
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
J Chromatogr A. 2000 Feb 25;871(1-2):321-30
pubmed: 10735312